Literature DB >> 3042255

Proinsulin, insulin, and C-peptide in cystic fibrosis after an oral glucose tolerance test.

S G Hartling1, S Garne, C Binder, C Heilmann, W Petersen, K E Petersen, C Koch.   

Abstract

The beta-cell response to an oral glucose load was studied in 22 patients with cystic fibrosis (CF) by means of insulin, C-peptide and proinsulin, and the results compared with those from 20 healthy sex and age matched controls. According to WHO criteria two had diabetes mellitus, eight had impaired glucose tolerance and twelve had normal glucose tolerance. All patients showed lower insulin and C-peptide levels than the controls at 30 minutes. However the insulin and C-peptide responses were sustained so that the areas under the curves were comparable between controls, CF patients with normal glucose tolerance, and CF patients with impaired glucose tolerance. By contrast, the area under the proinsulin curve was significantly higher in the CF patients with impaired glucose tolerance compared with both controls (p less than 0.05) and with the CF normal glucose tolerance group (p less than 0.02). In the CF patients with impaired glucose tolerance the proinsulin level was significantly elevated at 120 minutes (median 50 pmol/l) and at 180 minutes (29 pmol/l) as compared with the controls (24 and 19 pmol/l p less than 0.01) and with the CF patients with normal glucose tolerance (21 and 16 pmol/l p less than 0.01). These data confirm that impaired glucose tolerance and diabetes is frequent in cystic fibrosis. The elevated proinsulin immunoreactive material in CF patients with impaired glucose tolerance may partly compensate for the relative insufficient insulin response found in these patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042255

Source DB:  PubMed          Journal:  Diabetes Res        ISSN: 0265-5985


  7 in total

1.  Glucose tolerance in cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; G Erichsen; J Nerup; C Koch
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

Review 2.  Diagnosis, screening, and management of cystic fibrosis-related diabetes.

Authors:  Antoinette Moran
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

3.  Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis.

Authors:  R W Holl; E Heinze; A Wolf; M Rank; W M Teller
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

Review 4.  Cystic fibrosis related diabetes.

Authors:  Donal O'Shea; Jean O'Connell
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

5.  Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas.

Authors:  Alain Boom; Pascale Lybaert; Jean-François Pollet; Paul Jacobs; Hassan Jijakli; Philippe E Golstein; Abdullah Sener; Willy J Malaisse; Renaud Beauwens
Journal:  Endocrine       Date:  2007-11-27       Impact factor: 3.633

6.  Proportional proinsulin responses in first-degree relatives of patients with type 2 diabetes mellitus.

Authors:  M E Røder; J Eriksson; S G Hartling; L Groop; C Binder
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

7.  Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass.

Authors:  Aliye Uc; Alicia K Olivier; Michelle A Griffin; David K Meyerholz; Jianrong Yao; Maisam Abu-El-Haija; Katherine M Buchanan; Oriana G Vanegas Calderón; Marwa Abu-El-Haija; Alejandro A Pezzulo; Leah R Reznikov; Mark J Hoegger; Michael V Rector; Lynda S Ostedgaard; Peter J Taft; Nick D Gansemer; Paula S Ludwig; Emma E Hornick; David A Stoltz; Katie L Ode; Michael J Welsh; John F Engelhardt; Andrew W Norris
Journal:  Clin Sci (Lond)       Date:  2015-01       Impact factor: 6.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.